EFFECTIVITY OF SELECTING BALOXAVIR AS AN ALTERNATIVE TREATMENT FOR INFLUENZA: A SCOPING REVIEW
DOI:
https://doi.org/10.22159/ijap.2025.v17s2.16Keywords:
Antiviral agent, Baloxavir, Effectiveness, InfluenzaAbstract
This scoping review evaluates the effectiveness of baloxavir, a cap-dependent endonuclease inhibitor, as an alternative antiviral treatment for influenza. A scoping review followed PRISMA guidelines, utilizing databases such as PubMed, SCOPUS, Science Direct, and cochrane to identify relevant studies published until November 2024. The review included 24 studies comparing baloxavir to placebo and other antiviral agents. It indicated that baloxavir significantly reduces the duration of influenza symptoms and has a favorable safety profile compared to oseltamivir and other neuraminidase inhibitors. Specifically, baloxavir demonstrated a shorter time to symptom relief and lower incidence of gastrointestinal side effects, particularly in younger populations. However, concerns regarding the emergence of viral variants that may impact treatment efficacy were noted. Overall, while baloxavir shows promise as an effective treatment option for influenza, further research across diverse populations is necessary to validate its global applicability and safety.
References
Abraham GM, Morton JB, Saravolatz LD. Baloxavir: a novel antiviral agent in the treatment of influenza. Clin Infect Dis. 2020 Oct 23;71(7):1790-4. doi: 10.1093/cid/ciaa107, PMID 32020174.
Dyawara JP, Yulianti T. Hubungan pengetahuan dan perilaku swamedikasi common cold pada masyarakat di kecamatan ngawi. Usadha J Pharm. 2022 Nov 30;1(4):402-16. doi: 10.23917/ujp.v1i4.99.
Swierczynska M, Mirowska Guzel DM, Pindelska E. Antiviral drugs in influenza. Int J Environ Res Public Health. 2022 Mar 4;19(5):3018. doi: 10.3390/ijerph19053018, PMID 35270708.
Fauzi A, Saifudin A, Hidayatullah MH, Shabrina RH. Antiviral potential of 4-(4-hydroxy-3,5-dimethylphenyl)-6-Methyl-2-Oxo-1,2,3,4-Tetrahydropyrimidine-5-Carboxylate (THPM) against Newcastle disease virus: synthesis and in ovo activity. Asian J Green Chem. 2025 Mar 1;9(2):181-92. doi: 10.48309/AJGC.2025.485842.1582.
Miftahudin A, Kartinah A. Hubungan pengetahuan tentang flu burung dengan sikap masyarakat yang memelihara unggas di wilayah Mojogedang. Jurnal Berita Ilmu Keperawatan. 2008 Dec;1(4):157-62. doi: 10.23917/bik.v1i4.3728.
Kanso M, Omeiche ZA, Hijazi MA, El Lakany A, Ela MA. Antiviral potential of herbal medicine in fight COVID-19 pandemic reinvestigation of herbal monograph. Int J Pharm Pharm Sci. 2024 Sep 1;16(9):18-25. doi: 10.22159/ijpps.2024v16i9.51681.
Kalil AC, Thomas PG. Influenza virus related critical illness: pathophysiology and epidemiology. Crit Care. 2019 Dec 19;23(1):258. doi: 10.1186/s13054-019-2539-x, PMID 31324202.
Nypaver C, Dehlinger C, Carter C. Influenza and influenza vaccine: a review. J Midwifery Womens Health. 2021 Jan;66(1):45-53. doi: 10.1111/jmwh.13203, PMID 33522695.
Tyrrell CS, Allen JL, Gkrania Klotsas E. Influenza: epidemiology and hospital management. Medicine (Abingdon). 2021 Dec;49(12):797-804. doi: 10.1016/j.mpmed.2021.09.015, PMID 34849086.
Ryu S, Cowling BJ. Human influenza epidemiology. Cold Spring Harb Perspect Med. 2021 Dec;11(12):a038356. doi: 10.1101/cshperspect.a038356, PMID 32988982.
Odnovorov AI, Grebennikova ТV, Pleteneva TV, Garaev TM, Uspenskaya EV, Khodorovich NA. Physicochemical properties and biological activity of the new antiviral substance. Int J Appl Pharm. 2020 Jul 1;12(4):237-42. doi: 10.22159/ijap.2020v12i4.38136.
O Hanlon R, Shaw ML. Baloxavir marboxil: the new influenza drug on the market. Curr Opin Virol. 2019 Apr;35:14-8. doi: 10.1016/j.coviro.2019.01.006, PMID 30852344.
Fang Q, Wang D. Advanced researches on the inhibition of influenza virus by favipiravir and baloxavir. Biosafety and Health. 2020 Jun;2(2):64-70. doi: 10.1016/j.bsheal.2020.04.004.
Sujono TA, Karuniawati H, Dai M, Sar EN, Roshitasari E, Dewi SJ, Syahputri JA, Rachmalia FM, Hertaliyana JA, Sanjaya MR. Sosialisasi pencegahan dan penanganan flu singapura serta waspada penggunaan obat melalui dagusibu kepada masyarakat desa potronayan kecamatan nogosari boyolali. Inovasi Jurnal Pengabdian Masyarakat. 2024 Aug 18;2(2):283-94. doi: 10.54082/ijpm.540.
Ikematsu H, Hayden FG, Kawaguchi K, Kinoshita M, De Jong MD, Lee N. Baloxavir marboxil for prophylaxis against influenza in household contacts. N Engl J Med. 2020 Jul 23;383(4):309-20. doi: 10.1056/NEJMoa1915341, PMID 32640124.
Portsmouth S, Hayden FG, Kawaguchi K, Ishibashi T, Kinoshita M, Shishido T. Baloxavir treatment in adolescents with acute influenza: subgroup analysis from the capstone-1 trial. J Pediatric Infect Dis Soc. 2021 Apr 30;10(4):477-84. doi: 10.1093/jpids/piaa145, PMID 33340316.
Ishiguro N, Morioka I, Nakano T, Furukawa M, Tanaka S, Kinoshita M. Clinical and virological outcomes with baloxavir compared with oseltamivir in pediatric patients aged 6 to < 12 y with influenza: an open label randomized active controlled trial protocol. BMC Infect Dis. 2021 Dec 9;21(1):777. doi: 10.1186/s12879-021-06494-w, PMID 34372769.
Yoshino Y, Kitazawa T, Ota Y. Clinical efficacy of baloxavir marboxil in the treatment of seasonal influenza in adult patients: a prospective observational study. Int J Gen Med. 2020 Oct;13:735-41. doi: 10.2147/IJGM.S273266, PMID 33061543.
Ikematsu H, Baba T, Saito MM, Kinoshita M, Miyazawa S, Hata A. Comparative effectiveness of baloxavir marboxil and oseltamivir treatment in reducing household transmission of influenza: a post hoc analysis of the blockstone trial. Influ Other Respir Viruses. 2024 May 6;18(5):e13302. doi: 10.1111/irv.13302, PMID 38706384.
Komeda T, Takazono T, Hosogaya N, Miyazaki T, Ogura E, Iwata S. Comparison of hospitalization incidence in influenza outpatients treated with baloxavir marboxil or neuraminidase inhibitors: a health insurance claims database study. Clin Infect Dis. 2021 Sep 7;73(5):e1181-90. doi: 10.1093/cid/ciaa1870, PMID 33354728.
Komeda T, Takazono T, Hosogaya N, Ogura E, Fujiwara M, Miyauchi H. Comparison of household transmission of influenza virus from index patients treated with baloxavir marboxil or neuraminidase inhibitors: a health insurance claims database study. Clin Infect Dis. 2021 Jun 1;72(11):e859-67. doi: 10.1093/cid/ciaa1622, PMID 33103200.
Wagatsuma K, Saito R, Chon I, Phyu WW, Fujio K, Kawashima T. Duration of fever and symptoms in influenza-infected children treated with baloxavir marboxil during the 2019-2020 season in Japan and detection of influenza virus with the PA E23K substitution. Antiviral Res. 2022 May;201:105310. doi: 10.1016/j.antiviral.2022.105310, PMID 35358601.
Umemura T, Mutoh Y, Kawamura T, Saito M, Mizuno T, Ota A. Efficacy of baloxavir marboxil on household transmission of influenza infection. J Pharm Health Care Sci. 2020 Dec 1;6(1):21. doi: 10.1186/s40780-020-00178-4, PMID 33014405.
Sonoyama T, Sakaguchi H, Koshimichi H, Noshi T, Tsuchiya K, Uehara T. Open-label study of the safety, pharmacokinetics, and effectiveness of a 2 mg/kg dose of baloxavir marboxil 2% granules in children andlt; 20 kg with influenza. J Infect Chemother. 2021 Aug;27(8):1223-9. doi: 10.1016/j.jiac.2021.05.009, PMID 34045119.
Liao G, Xia M, Jiang Y, Chen H, Liao W, Peng J. Prospective observational study of baloxavir marboxil in adults and adolescents with uncomplicated influenza from China. Front Microbiol. 2023 Nov 27;14:1292735. doi: 10.3389/fmicb.2023.1292735, PMID 38088961.
Cai J, Wang H, Ye X, Lu S, Tan Z, Li Z. Real-world effectiveness and safety of Baloxavir Marboxil or oseltamivir in outpatients with uncomplicated influenza a: an ambispective, observational, multi-center study. Front Microbiol. 2024 Jul 23;15:1428095. doi: 10.3389/fmicb.2024.1428095, PMID 39109213.
Li Y, Wang X, Liao Y, Zeng Y, Lin W, Zhuang W. Safety analysis of oseltamivir and Baloxavir Marboxil after market approval: a pharmacovigilance study based on the FDA adverse event reporting system. BMC Infect Dis. 2024 May 9;24(1):446. doi: 10.1186/s12879-024-09339-4, PMID 38724914.
Ge X, Chen Y, Wu W, Lu J, Wang Y, Li Z. Safety and effectiveness of baloxavir marboxil and oseltamivir for influenza in children: a real-world retrospective study in China. Front Pediatr. 2024 Jul 29;12:1418321. doi: 10.3389/fped.2024.1418321, PMID 39135856.
Nakazawa M, Hara K, Komeda T, Ogura E. Safety and effectiveness of baloxavir marboxil for the treatment of influenza in Japanese clinical practice: A postmarketing surveillance of more than 3000 patients. J Infect Chemother. 2020 Jul;26(7):729-35. doi: 10.1016/j.jiac.2020.04.014, PMID 32409018.
Qiu C, Cheng F, Ye X, Wu Z, Ning H, Liu S. Study on the clinical efficacy and safety of baloxavir marboxil tablets in the treatment of influenza A. Front Med (Lausanne). 2024 Apr 5;11:1339368. doi: 10.3389/fmed.2024.1339368, PMID 38646560.
Uehara T, Hayden FG, Kawaguchi K, Omoto S, Hurt AC, De Jong MD. Treatment-emergent influenza variant viruses with reduced baloxavir susceptibility: impact on clinical and virologic outcomes in uncomplicated influenza. J Infect Dis. 2020;221(3):346-55. doi: 10.1093/infdis/jiz244, PMID 31309975.
Yoshii N, Tochino Y, Fujioka M, Sakazaki H, Maruyama N, Asai K. The comparison of the efficacy of baloxavir and neuraminidase inhibitors for patients with influenza a in clinical practice. Intern Med. 2020 Jun 15;59(12):1509-13. doi: 10.2169/internalmedicine.4117-19, PMID 32536677.
Goto T, Kawai N, Bando T, Takasaki Y, Shindo S, Tani N. Virological and clinical outcomes in outpatients treated with baloxavir or neuraminidase inhibitors for A(H3N2) influenza: A multicenter study of the 2022-2023 season. Antiviral Res. 2024 Apr;224:105853. doi: 10.1016/j.antiviral.2024.105853, PMID 38430970.
Gong Z, Yu X, Han Q, Lu L, Liu Y, Pei B. Effectiveness and safety comparison of baloxavir marboxil versus oseltamivir in the treatment of influenza b: a real-world cohort study. Available from: https://ssrn.com/abstract=5210783. [Last accessed on 23 May 2025].
Macesic N, Laplante JM, Aaron JG, DiMango EA, Miko BA, Pereira MR. Baloxavir treatment of oseltamivir-resistant influenza A/H1pdm09 in two immunocompromised patients. Transpl Infect Dis. 2021 Jun 1;23(3):e13542. doi: 10.1111/tid.13542, PMID 33278052.
Retout S, De Buck S, Jolivet S, Duval V, Cosson V. A pharmacokinetics–time to alleviation of symptoms model to support extrapolation of baloxavir marboxil clinical efficacy in different ethnic groups with influenza A or B. Clin Pharmacol Ther. 2022 Aug 1;112(2):372-81. doi: 10.1002/cpt.2648, PMID 35585696.
Baker J, Block SL, Matharu B, Burleigh Macutkiewicz L, Wildum S, Dimonaco S. Baloxavir marboxil single-dose treatment in influenza-infected children: a randomized, double-blind, active controlled phase 3 safety and efficacy trial (mini stone-2). Pediatr Infect Dis J. 2020 Aug 1;39(8):700-5. doi: 10.1097/INF.0000000000002747, PMID 32516282.
Collins C, Cagas SE, Han J, Delporte ML, Retout S. Baloxavir marboxil treatment of influenza in renally impaired patients: post hoc analysis of capstone-2. American Society of Nephrology (ASN); 2023 Nov.
Rahmania TA, Harahap Y, Sandy K. Azithromycin and oseltamivir quantification method developed and validated using liquid chromatography-tandem mass spectrometry in dried blood spot. Int J Appl Pharm. 2024;16(2):182-7. doi: 10.22159/ijap.2024v16i2.49051.
Afni N, Suharjono S. Molnupiravir-the first oral antiviral for COVID-19: a literature review. Pharmacon. 2022 Jun 25;19(1):45-61. doi: 10.23917/pharmacon.v19i1.17330.
Published
How to Cite
Issue
Section
Copyright (c) 2025 DEVI U. ROSYIDAH, FAHMI D. MUMTAZ, AUFA F. F. FARMA, REYDOVAN PUTRA, HANIF N. KHAIRUDDIN
This work is licensed under a Creative Commons Attribution 4.0 International License.
